Received Jul 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 2 | — | — |
Received First dose In May 2023, and the 2nd Dose July 2023, and Another Dose June 10, 2025; Initial report received on 10-Jul-2025. A pharmacy intern in the reported that a 27-year-old female received the first dose of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization in May-2023, the second dose in Jul-2023, and a third dose on 10-Jun-2025. No medical history or concomitant medications were reported. In May-2023, the patient received dose 1 of a hepatitis B vaccine HEPLISAV-B (lot number, expiration date, NDC number, route, and site not available). In Jul-2023, the patient received dose 2 of HEPLISAV-B (lot number, expiration date, NDC number, route, and site not available). On 10-Jun-2025, after receiving the second dose of HEPLISAV-B, the patient received dose 3 of a HEPLISAV-B (lot number 945665, expiration date 31-Jan-2027, NDC number 43528-003-05) intramuscularly in the left arm. Previous doses were received at a different pharmacy than the third dose. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.